Dear KAND Families,
It is with great hope for the future that I share this news—news with enormous impact on our mission to discover treatment for our loved ones living with KIF1A Associated Neurological Disorder.
This morning Ovid Therapeutics announced a research collaboration with the Chung Lab at Columbia University. Ovid and Columbia have joined forces to identify, develop and advance new treatments into future clinical trials for KIF1A Associated Neurological Disorder and other rare conditions.
Every KAND family should know this: we are closer to treatment today because of you. Our community shows up every single day to improve the lives of those affected by KAND. Together, we relentlessly work to find treatment by driving and engaging in research, telling our stories and supporting each other in the most difficult of times.
It’s hard to show up these days, but we do. We show up and fight through isolated days at home watching our children’s health deteriorate. We show up and fight through the falls, the stitches, the seizures, the pain and uncertainty. We fight through the unthinkable. Our community shows up together to change the course of this horrific disease. Today our community of patients, families, physicians and researchers is even stronger. Today a relentless team showed up to join our mission. Today we welcome Ovid Therapeutics to our community of people working to bring treatments and cures to our families.
Join me in extending our thanks to Ovid for showing up and answering the call, and to Chung Lab for continuing to work tirelessly at our side. This collaboration represents significant progress. Together we will work with relentless urgency to bring treatment to every individual living with KIF1A Associated Neurological Disorder.
Read the press release here, with messages from Ovid Therapeutics President and Chief Medical Officer Amit Rakhit, M.D., MBA, and Columbia University’s Wendy Chung, MD, PhD.